Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Paul Edward Sax, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. M01RR002635 (GOTTLIEB, GARY L) Dec 1, 1984 - Nov 30, 2004
    NIH/NCRR
    General Clinical Research Center
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med. 2020 Sep 17. PMID: 32941052.
    Citations:    
  2. Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK, Wei X, Carter CC, Zhong L, Brainard DM, Melbourne K, Das M, Stellbrink HJ, Post FA, Waters L, Koethe JR. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2020 Sep 12; 71(6):1379-1389. PMID: 31606734.
    Citations:    
  3. Dandachi D, Geiger G, Montgomery MW, Karmen-Tuohy S, Golzy M, Antar AAR, Llibre JM, Camazine M, Díaz-De Santiago A, Carlucci PM, Zacharioudakis IM, Rahimian J, Wanjalla CN, Slim J, Arinze F, Kratz AMP, Jones JL, Patel SM, Kitchell E, Francis A, Ray M, Koren DE, Baddley JW, Hill B, Sax PE, Chow J. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients with HIV and Coronavirus Disease-19. Clin Infect Dis. 2020 Sep 09. PMID: 32905581.
    Citations:    
  4. Sax PE, Rockstroh JK, Luetkemeyer AF, Yazdanpanah Y, Ward D, Trottier B, Rieger A, Liu H, Acosta R, Collins SE, Brainard DM, Martin H. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV. Clin Infect Dis. 2020 Jul 15. PMID: 32668455.
    Citations:    
  5. Neilan TG, Nguyen KL, Zaha VG, Chew KW, Morrison L, Ntusi NAB, Toribio M, Awadalla M, Drobni ZD, Nelson MD, Burdo TH, Van Schalkwyk M, Sax PE, Skiest DJ, Tashima K, Landovitz RJ, Daar E, Wurcel AG, Robbins GK, Bolan RK, Fitch KV, Currier JS, Bloomfield GS, Desvigne-Nickens P, Douglas PS, Hoffmann U, Grinspoon SK, Ribaudo H, Dawson R, Goetz MB, Jain MK, Warner A, Szczepaniak LS, Zanni MV. Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. J Infect Dis. 2020 Jul 09; 222(Supplement_1):S63-S69. PMID: 32645158.
    Citations:    
  6. Barnes M, Sax PE. Challenges of "Return to Work" in an Ongoing Pandemic. N Engl J Med. 2020 08 20; 383(8):779-786. PMID: 32558484.
    Citations:    
  7. Jilg N, Garcia-Broncano P, Peluso M, Segal FP, Bosch RJ, Roberts-Toler C, Chen SMY, Van Dam CN, Keefer MC, Kuritzkes DR, Landay AL, Deeks S, Yu XG, Sax PE, Li JZ. Hiv Controllers Maintain Viral Suppression Despite Waning T-Cell Responses On Art. J Infect Dis. 2020 Jun 04. PMID: 32496516.
    Citations:    
  8. Cevik M, Orkin C, Sax PE. Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases. Open Forum Infect Dis. 2020 Jun; 7(6):ofaa202. PMID: 32587877.
    Citations:    
  9. Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020 06; 7(6):e389-e400. PMID: 32504574.
    Citations:    
  10. Sun X, Hua S, Gao C, Blackmer JE, Ouyang Z, Ard K, Ciaranello A, Yawetz S, Sax PE, Rosenberg ES, Lichterfeld M, Yu XG. Immune-profiling of ZIKV-infected patients identifies a distinct function of plasmacytoid dendritic cells for immune cross-regulation. Nat Commun. 2020 05 15; 11(1):2421. PMID: 32415086.
    Citations:    
  11. Li JZ, Segal FP, Bosch RJ, Lalama CM, Roberts-Toler C, Delagreverie H, Getz R, Garcia-Broncano P, Kinslow J, Tressler R, Van Dam CN, Keefer M, Carrington M, Lichterfeld M, Kuritzkes D, Yu XG, Landay A, Sax PE. Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. Clin Infect Dis. 2020 Apr 10; 70(8):1636-1642. PMID: 31131858.
    Citations:    
  12. Hyle EP, Scott JA, Sax PE, Millham LRI, Dugdale CM, Weinstein MC, Freedberg KA, Walensky RP. Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States. Clin Infect Dis. 2020 Mar 17; 70(7):1353-1363. PMID: 31055599.
    Citations:    
  13. Thompson M, Orkin C, Molina JM, Sax P, Cahn P, Squires K, Xu X, Rodgers A, Kumar S, Teppler H, Martin E, Hanna G, Hwang C. Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis. Clin Infect Dis. 2020 Mar 17; 70(7):1336-1343. PMID: 31121013.
    Citations:    
  14. Taiwo BO, Quiñones-Mateu ME, Smith K, Zheng L, Gulick R, Nyaku AN, Sax PE, Ha B, Kumwenda J, Olefsky M, Godfrey C, Wallis C. Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy. AIDS Res Hum Retroviruses. 2020 04; 36(4):254-255. PMID: 31914799.
    Citations:    
  15. Richterman A, Sax PE. Antiretroviral therapy in older people with HIV. Curr Opin HIV AIDS. 2020 03; 15(2):118-125. PMID: 31990705.
    Citations:    
  16. Patel SV, Jayaweera DT, Althoff KN, Eron JJ, Radtchenko J, Mills A, Moyle G, Santiago S, Sax PE, Gillman J, Mounzer K, Elion RA, Huhn GD. Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV. PLoS One. 2020; 15(2):e0228847. PMID: 32053682.
    Citations:    
  17. Millham LRI, Scott JA, Sax PE, Shebl FM, Reddy KP, Losina E, Walensky RP, Freedberg KA. Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States. J Acquir Immune Defic Syndr. 2020 02 01; 83(2):148-156. PMID: 31929403.
    Citations:    
  18. Corsi-Vasquez G, Ostrosky-Zeichner L, Pilkington EF, Sax PE. Point-Counterpoint: Should Serum ß-d-Glucan Testing Be Used for the Diagnosis of Pneumocystis jirovecii Pneumonia? J Clin Microbiol. 2019 12 23; 58(1). PMID: 31434728.
    Citations:    
  19. Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV. 2020 01; 7(1):e16-e26. PMID: 31740348.
    Citations:    
  20. Sax PE. Nearly Two Decades Later, Exciting Progress in HIV, But Challenges Remain. Infect Dis Clin North Am. 2019 09; 33(3):xiii-xiv. PMID: 31395148.
    Citations:    
  21. Gupta SK, Post FA, Arribas JR, Eron JJ, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019 07 15; 33(9):1455-1465. PMID: 30932951.
    Citations:    
  22. Braun DA, Henderson GV, Sax PE, Miller AL, Loscalzo J. A Disturbing Decline. N Engl J Med. 2019 Jun 06; 380(23):2257-2262. PMID: 31167056.
    Citations:    
  23. Braun DA, Simchowitz B, Henderson GV, Sax PE, Vaidya A. A Disturbing Decline. N Engl J Med. 2019 May 30; 380(22):e42. PMID: 31141638.
    Citations:    
  24. Stellbrink HJ, Arribas JR, Stephens JL, Albrecht H, Sax PE, Maggiolo F, Creticos C, Martorell CT, Wei X, Acosta R, Collins SE, Brainard D, Martin H. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019 06; 6(6):e364-e372. PMID: 31068272.
    Citations:    
  25. Nyaku AN, Zheng L, Gulick RM, Olefsky M, Berzins B, Wallis CL, Godfrey C, Sax PE, Acosta EP, Haas DW, Smith KY, Sha BE, Van Dam CN, Taiwo BO. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500?000 copies/mL: week 48 outcomes from ACTG 5353. J Antimicrob Chemother. 2019 05 01; 74(5):1376-1380. PMID: 30668695.
    Citations:    Fields:    
  26. Bourque DL, Solomon DA, Sax PE. Health Considerations for HIV-Infected International Travelers. Curr Infect Dis Rep. 2019 Apr 12; 21(5):16. PMID: 30980287.
    Citations:    
  27. Dugdale CM, Ciaranello AL, Bekker LG, Stern ME, Myer L, Wood R, Sax PE, Abrams EJ, Freedberg KA, Walensky RP. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study. Ann Intern Med. 2019 05 07; 170(9):614-625. PMID: 30934067.
    Citations:    
  28. Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Acosta EP, Mager DE, Morse GD. Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202. Antimicrob Agents Chemother. 2019 04; 63(4). PMID: 30642925.
    Citations:    Fields:    
  29. Hulgan T, Ramsey BS, Koethe JR, Samuels DC, Gerschenson M, Libutti DE, Sax PE, Daar ES, McComsey GA, Brown TT. Relationships Between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons With HIV After 96 Weeks of Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2019 03 01; 80(3):358-366. PMID: 30531304.
    Citations:    Fields:    
  30. Li JZ, Sax PE, Marconi VC, Fajnzylber J, Berzins B, Nyaku AN, Fichtenbaum CJ, Wilkin T, Benson CA, Koletar SL, Lorenzo-Redondo R, Taiwo BO. No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial. Open Forum Infect Dis. 2019 Mar; 6(3):ofz056. PMID: 30895201.
    Citations:    
  31. Hale TM, Guardigni V, Roitmann E, Vegreville M, Brawley B, Woodbury E, Storer TW, Sax PE, Montano M. Middle-Aged Men With HIV Have Diminished Accelerometry-Based Activity Profiles Despite Similar Lab-Measured Gait Speed: Pilot Study. JMIR Mhealth Uhealth. 2019 02 01; 7(2):e11190. PMID: 30707104.
    Citations:    
  32. Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, Martin EA. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019 02 01; 68(4):535-544. PMID: 30184165.
    Citations: 2     Fields:    
  33. Gianella S, Marconi VC, Berzins B, Benson CA, Sax P, Fichtenbaum CJ, Wilkin T, Vargas M, Deng Q, Oliveira MF, Moser C, Taiwo BO. Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy. J Acquir Immune Defic Syndr. 2018 12 15; 79(5):e112-e114. PMID: 30383591.
    Citations:    Fields:    
  34. Cahn P, Sax PE, Squires K, Molina JM, Ratanasuwan W, Rassool M, Bloch M, Xu X, Zhou Y, Homony B, Hepler D, Teppler H, Hanna GJ, Nguyen BY, Greaves W. Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial. J Acquir Immune Defic Syndr. 2018 08 15; 78(5):589-598. PMID: 29771789.
    Citations:    Fields:    
  35. Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Wei X, Collins SE, Cheng A. Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide. AIDS. 2018 07 31; 32(12):1723-1725. PMID: 29794828.
    Citations:    Fields:    
  36. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, Sax PE, Smith DM, Thompson MA, Buchbinder SP, Del Rio C, Eron JJ, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018 07 24; 320(4):379-396. PMID: 30043070.
    Citations: 3     Fields:    Translation:Humans
  37. Haas DW, Bradford Y, Verma A, Verma SS, Eron JJ, Gulick RM, Riddler SA, Sax PE, Daar ES, Morse GD, Acosta EP, Ritchie MD. Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics. 2018 07; 28(7):179-187. PMID: 29847509.
    Citations:    Fields:    
  38. Tran T, Guardigni V, Pencina KM, Amato AA, Floyd M, Brawley B, Mozeleski B, McKinnon J, Woodbury E, Heckel E, Li Z, Storer T, Sax PE, Montano M. Atypical Skeletal Muscle Profiles in Human Immunodeficiency Virus-Infected Asymptomatic Middle-Aged Adults. Clin Infect Dis. 2018 06 01; 66(12):1918-1927. PMID: 29293942.
    Citations:    Fields:    
  39. Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E, Haas D, Smith KY, Sha B, Van Dam C, Gulick RM. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis. 2018 05 17; 66(11):1689-1697. PMID: 29253097.
    Citations: 6     Fields:    
  40. Taiwo BO, Marconi VC, Berzins B, Moser CB, Nyaku AN, Fichtenbaum CJ, Benson CA, Wilkin T, Koletar SL, Colasanti J, Acosta EP, Li JZ, Sax PE. Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Clin Infect Dis. 2018 05 17; 66(11):1794-1797. PMID: 29293895.
    Citations: 4     Fields:    
  41. Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018 05; 5(5):e211-e220. PMID: 29592840.
    Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
  42. Buchanan AL, Hudgens MG, Cole SR, Mollan KR, Sax PE, Daar ES, Adimora AA, Eron JJ, Mugavero MJ. Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights. J R Stat Soc Ser A Stat Soc. 2018 Oct; 181(4):1193-1209. PMID: 30555215.
    Citations:    
  43. Sax P, DeJesus E, Wohl D, DeMorin J, McColl D, Piontkowsky D, Cohen C, Wang H, White K, Callebaut C, Rhee M, Das M, Quirk E. Virological outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in antiretroviral-naive HIV-1-infected participants with baseline HIV-1 RNA =1,000,000 copies/ml: a post hoc analysis of Phase III clinical trials. Antivir Ther. 2018; 23(1):95-99. PMID: 28799919.
    Citations:    Fields:    
  44. Sun X, Hua S, Chen HR, Ouyang Z, Einkauf K, Tse S, Ard K, Ciaranello A, Yawetz S, Sax P, Rosenberg ES, Lichterfeld M, Yu XG. Transcriptional Changes during Naturally Acquired Zika Virus Infection Render Dendritic Cells Highly Conducive to Viral Replication. Cell Rep. 2017 Dec 19; 21(12):3471-3482. PMID: 29262327.
    Citations: 5     Fields:    Translation:HumansCells
  45. Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Yang Y, Wilding GE, Morse GD. Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit. 2017 12; 39(6):596-603. PMID: 29135907.
    Citations:    Fields:    Translation:HumansCells
  46. Borre ED, Hyle EP, Paltiel AD, Neilan AM, Sax PE, Freedberg KA, Weinstein MC, Walensky RP. The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. J Infect Dis. 2017 10 17; 216(7):798-807. PMID: 29029344.
    Citations:    Fields:    Translation:Humans
  47. Losina E, Hyle EP, Borre ED, Linas BP, Sax PE, Weinstein MC, Rusu C, Ciaranello AL, Walensky RP, Freedberg KA. Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States. Clin Infect Dis. 2017 10 15; 65(8):1266-1271. PMID: 28605504.
    Citations: 8     Fields:    Translation:Humans
  48. Koullias Y, Sax PE, Fields NF, Walensky RP, Hyle EP. Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus? Clin Infect Dis. 2017 10 15; 65(8):1274-1281. PMID: 28605418.
    Citations: 1     Fields:    Translation:HumansCells
  49. Beckman JA, Wood BR, Ard KL, Price CN, Solomon DA, Zuflacht JP, Milian J, Prenner JC, Sax PE. Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir. PLoS One. 2017; 12(10):e0181993. PMID: 29023508.
    Citations: 1     Fields:    Translation:HumansCells
  50. LaFleur J, Bress AP, Rosenblatt L, Crook J, Sax PE, Myers J, Ritchings C. Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. AIDS. 2017 09 24; 31(15):2095-2106. PMID: 28692532.
    Citations: 2     Fields:    Translation:Humans
  51. Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L, Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R, Teppler H. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV. 2017 11; 4(11):e486-e494. PMID: 28918877.
    Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
  52. Mollan KR, Tierney C, Hellwege JN, Eron JJ, Hudgens MG, Gulick RM, Haubrich R, Sax PE, Campbell TB, Daar ES, Robertson KR, Ventura D, Ma Q, Edwards DRV, Haas DW. Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants. J Infect Dis. 2017 09 01; 216(5):554-564. PMID: 28931220.
    Citations: 5     Fields:    Translation:Humans
  53. Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J, Garner W, Custodio J, White K, SenGupta D, Cheng A, Quirk E. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017 Nov 04; 390(10107):2073-2082. PMID: 28867499.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  54. Arribas JR, Thompson M, Sax PE, Haas B, McDonald C, Wohl DA, DeJesus E, Clarke AE, Guo S, Wang H, Callebaut C, Plummer A, Cheng A, Das M, McCallister S. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. J Acquir Immune Defic Syndr. 2017 06 01; 75(2):211-218. PMID: 28282300.
    Citations: 12     Fields:    Translation:Humans
  55. Parker RA, Rabideau DJ, Sax PE, Tierney C, Daar ES, Collier AC, Losina E, Freedberg KA. Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study. Clin Infect Dis. 2017 Jun 01; 64(11):1612-1614. PMID: 28329243.
    Citations:    Fields:    Translation:HumansCellsCTClinical Trials
  56. Paltiel AD, Zheng A, Weinstein MC, Gaynes MR, Wood R, Freedberg KA, Sax PE, Walensky RP. Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa. Open Forum Infect Dis. 2017; 4(2):ofx081. PMID: 28680903.
    Citations: 1     
  57. Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Peloquin J, Wei X, White K, Cheng A, Martin H, Quirk E. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017 04; 4(4):e154-e160. PMID: 28219610.
    Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
  58. Walsh CE, Workowski K, Terrault NA, Sax PE, Cohen A, Bowlus CL, Kim AY, Hyland RH, Han B, Wang J, Stamm LM, Brainard DM, McHutchison JG, von Drygalski A, Rhame F, Fried MW, Kouides P, Balba G, Reddy KR. Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders. Haemophilia. 2017 Mar; 23(2):198-206. PMID: 28124511.
    Citations: 6     Fields:    Translation:Humans
  59. Freedberg KA, Sax PE. Improving on effective antiretroviral therapy: how good will a cure have to be? J Med Ethics. 2017 02; 43(2):71-73. PMID: 27920163.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  60. Massarotti EM, Sax PE, Compton L, Levy BD, Loscalzo J. Testing Limits. N Engl J Med. 2016 Oct 06; 375(14):1383-1388. PMID: 27705260.
    Citations:    Fields:    Translation:Humans
  61. Choi JY, Sungkanuparph S, Anekthananon T, Sax P, DeJesus E, Edelstein H, Nelson M, DeMorin J, Liu HC, Swamy R, Bahn J, Hwang S, Yang SY, Ng C, Piontkowsky D. Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials. Infect Chemother. 2016 Sep; 48(3):219-224. PMID: 27704731.
    Citations: 1     
  62. Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016 Jul 12; 316(2):191-210. PMID: 27404187.
    Citations: 93     Fields:    Translation:HumansCellsPHPublic Health
  63. Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, Tashima K, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, Zhong L, Callebaut C, Das M, Fordyce M. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr. 2016 May 01; 72(1):58-64. PMID: 26829661.
    Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
  64. Borges ÁH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES, Echeverría P, Gisslén M, Huedo-Medina TB, Hughes MD, Huppler Hullsiek K, Khabo P, Komati S, Kumar P, Lockman S, MacArthur RD, Maggiolo F, Matteelli A, Miro JM, Oka S, Petoumenos K, Puls RL, Riddler SA, Sax PE, Sierra-Madero J, Torti C, Lundgren JD. Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. Clin Infect Dis. 2016 07 15; 63(2):268-80. PMID: 27090986.
    Citations:    
  65. Pei PP, Weinstein MC, Li XC, Hughes MD, Paltiel AD, Hou T, Parker RA, Gaynes MR, Sax PE, Freedberg KA, Schackman BR, Walensky RP. Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. HIV Clin Trials. 2015 Nov; 16(6):207-18. PMID: 26651525.
    Citations:    Fields:    Translation:Humans
  66. Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. Clin Infect Dis. 2016 Mar 15; 62(6):784-91. PMID: 26658053.
    Citations: 7     Fields:    Translation:HumansCells
  67. Pennant KN, Costa JJ, Fuhlbrigge AL, Sax PE, Szent-Gyorgyi LE, Coblyn J, Desai SP. Improving Influenza and Pneumococcal Vaccination Rates in Ambulatory Specialty Practices. Open Forum Infect Dis. 2015 Dec; 2(4):ofv119. PMID: 26430697.
    Citations: 2     
  68. Abdalla M, Sax PE, Mostaghimi A, Miller AL, Loscalzo J. CLINICAL PROBLEM-SOLVING. On the Nose. N Engl J Med. 2015 Sep 03; 373(10):955-61. PMID: 26332551.
    Citations:    Fields:    Translation:HumansAnimals
  69. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015 Aug 20; 373(8):705-13. PMID: 26196665.
    Citations: 87     Fields:    Translation:HumansCellsCTClinical Trials
  70. Solomon DA, Sax PE. Current state and limitations of daily oral therapy for treatment. Curr Opin HIV AIDS. 2015 Jul; 10(4):219-25. PMID: 26049945.
    Citations: 3     Fields:    Translation:HumansCells
  71. Longenecker CT, Kitch D, Sax PE, Daar ES, Tierney C, Gupta SK, McComsey GA. Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s. J Acquir Immune Defic Syndr. 2015 Jun 01; 69(2):168-77. PMID: 26009829.
    Citations: 3     Fields:    Translation:Humans
  72. Sise ME, Backman ES, Wenger JB, Wood BR, Sax PE, Chung RT, Thadhani R, Kim AY. Short and long-term effects of telaprevir on kidney function in patients with hepatitis C virus infection: a retrospective cohort study. PLoS One. 2015; 10(4):e0124139. PMID: 25923243.
    Citations: 2     Fields:    Translation:Humans
  73. Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015 Jun 27; 385(9987):2606-15. PMID: 25890673.
    Citations: 74     Fields:    Translation:HumansCTClinical Trials
  74. Luz PM, Morris BL, Grinsztejn B, Freedberg KA, Veloso VG, Walensky RP, Losina E, Nakamura YM, Girouard MP, Sax PE, Struchiner CJ, Paltiel AD. Cost-effectiveness of genotype testing for primary resistance in Brazil. J Acquir Immune Defic Syndr. 2015 Feb 01; 68(2):152-61. PMID: 25415289.
    Citations: 3     Fields:    Translation:HumansCells
  75. Ross EL, Weinstein MC, Schackman BR, Sax PE, Paltiel AD, Walensky RP, Freedberg KA, Losina E. The clinical role and cost-effectiveness of long-acting antiretroviral therapy. Clin Infect Dis. 2015 Apr 01; 60(7):1102-10. PMID: 25583979.
    Citations: 11     Fields:    Translation:Humans
  76. Sax PE, Sypek A, Berkowitz BK, Morris BL, Losina E, Paltiel AD, Kelly KA, Seage GR, Walensky RP, Weinstein MC, Eron J, Freedberg KA. HIV cure strategies: how good must they be to improve on current antiretroviral therapy? PLoS One. 2014; 9(11):e113031. PMID: 25397616.
    Citations: 8     Fields:    Translation:Humans
  77. Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, Wang H, Callebaut C, Martin H, Fordyce MW, McCallister S. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014 Sep 01; 67(1):52-8. PMID: 24872136.
    Citations: 40     Fields:    Translation:HumansCellsCTClinical Trials
  78. Wyatt CM, Kitch D, Gupta SK, Tierney C, Daar ES, Sax PE, Ha B, Melbourne K, McComsey GA. Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. J Acquir Immune Defic Syndr. 2014 Sep 01; 67(1):36-44. PMID: 25117929.
    Citations: 6     Fields:    Translation:HumansCells
  79. Johnson JA, Sax PE. Beginning antiretroviral therapy for patients with HIV. Infect Dis Clin North Am. 2014 Sep; 28(3):421-38. PMID: 25151564.
    Citations: 1     Fields:    Translation:Humans
  80. Venuto CS, Mollan K, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Morse GD. Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. J Antimicrob Chemother. 2014 Dec; 69(12):3300-10. PMID: 25159623.
    Citations: 4     Fields:    Translation:Humans
  81. Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, Gulick RM, Na L, O'Keefe L, Robertson KR, Tierney C. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014 Jul 01; 161(1):1-10. PMID: 24979445.
    Citations: 32     Fields:    Translation:HumansCells
  82. Rhee C, Sax PE. Evaluation of fever and infections in cardiac surgery patients. Semin Cardiothorac Vasc Anesth. 2015 Jun; 19(2):143-53. PMID: 24958717.
    Citations: 1     Fields:    Translation:Humans
  83. Al-Hajjar SH, Frayha HH, Al-Hazmi M, Batawi R, McIntosh K, Sax PE, Al-Thawadi S, Al-Jumaah S, Busch MP, Hanhauser E, Kuritzkes DR, Li JZ, Henrich TJ. Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusion. AIDS. 2014 Jun 19; 28(10):1539-41. PMID: 24896805.
    Citations:    Fields:    Translation:HumansCells
  84. Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Melbourne KM, Ha B, McComsey GA. Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS. 2014 Jun 19; 28(10):1451-61. PMID: 24637543.
    Citations: 9     Fields:    Translation:Humans
  85. Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, Gulick RM, Daar ES, Sax PE, Riddler SA, Haubrich R, Salata RA, Currier JS. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infect Dis. 2014 Sep 15; 59(6):888-96. PMID: 24842909.
    Citations: 7     Fields:    Translation:HumansCells
  86. Sax PE. Initial therapy for HIV: can less be more? Lancet Infect Dis. 2014 Jul; 14(7):535-7. PMID: 24783987.
    Citations:    Fields:    Translation:HumansCells
  87. Gupta SK, Kitch D, Tierney C, Daar ES, Sax PE, Melbourne K, Ha B, McComsey GA. Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial. Open Forum Infect Dis. 2014 Mar; 1(1):ofu003. PMID: 25734077.
    Citations: 7     
  88. Wohl DA, Cohen C, Gallant JE, Mills A, Sax PE, Dejesus E, Zolopa A, Liu HC, Plummer A, White KL, Cheng AK, Rhee MS, Szwarcberg J. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014 Mar 01; 65(3):e118-20. PMID: 24256630.
    Citations: 21     Fields:    Translation:HumansCells
  89. Sax PE. A Welcome to Open Forum Infectious Diseases (OFID). Open Forum Infect Dis. 2014 Mar; 1(1):ofu001. PMID: 25734075.
    Citations:    
  90. McComsey GA, Kitch D, Sax PE, Tierney C, Jahed NC, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N, Daar ES. Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr. 2014 Feb 01; 65(2):167-74. PMID: 24121755.
    Citations: 23     Fields:    Translation:Humans
  91. Nachega JB, Parienti JJ, Uthman OA, Gross R, Dowdy DW, Sax PE, Gallant JE, Mugavero MJ, Mills EJ, Giordano TP. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis. 2014 May; 58(9):1297-307. PMID: 24457345.
    Citations: 71     Fields:    Translation:Humans
  92. Wood BR, Komarow L, Zolopa AR, Finkelman MA, Powderly WG, Sax PE. Beta-glucan for Pneumocystis pneumonia diagnosis in persons with AIDS: authors' reply. AIDS. 2013 Nov 28; 27(18):2967-8. PMID: 25119691.
    Citations: 1     Fields:    Translation:HumansAnimals
  93. Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis. 2014 Feb; 58(4):555-63. PMID: 24253247.
    Citations: 11     Fields:    Translation:HumansCells
  94. Grant PM, Tierney C, Budhathoki C, Daar ES, Sax PE, Collier AC, Fischl MA, Zolopa AR, Balamane M, Katzenstein D. Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202. HIV Clin Trials. 2013 Nov-Dec; 14(6):284-91. PMID: 24334181.
    Citations:    Fields:    Translation:Humans
  95. Hyle EP, Sax PE, Walensky RP. Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy. JAMA Intern Med. 2013 Oct 14; 173(18):1746-8. PMID: 23978894.
    Citations: 11     Fields:    Translation:Humans
  96. Johnson JA, Sax PE. Getting started with your HIV care. Posit Aware. 2013 Sep-Oct; 25(6):10-4. PMID: 24847580.
    Citations:    Fields:    Translation:Humans
  97. Wohl DA, Arnoczy G, Fichtenbaum CJ, Campbell T, Taiwo B, Hicks C, McComsey GA, Koletar S, Sax P, Tebas P, Ha B, Massengale K, Walsh K, Stein JH. Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther. 2014; 19(2):141-7. PMID: 23985706.
    Citations: 10     Fields:    Translation:Humans
  98. Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Tebas P, Melbourne K, Ha B, Jahed NC, McComsey GA. Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS. 2013 Aug 24; 27(13):2069-79. PMID: 24384588.
    Citations: 12     Fields:    Translation:HumansCells
  99. Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, Wohl D, Gallant JE, Liu HC, Plummer A, White KL, Cheng AK, Rhee MS, Szwarcberg J. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013 May 01; 63(1):96-100. PMID: 23392460.
    Citations: 35     Fields:    Translation:HumansCellsCTClinical Trials
  100. Wood BR, Komarow L, Zolopa AR, Finkelman MA, Powderly WG, Sax PE. Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms. AIDS. 2013 Mar 27; 27(6):967-72. PMID: 23698062.
    Citations: 5     Fields:    Translation:HumansAnimals
  101. Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, Paltiel AD, Schackman BR. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013 Jan 15; 158(2):84-92. PMID: 23318310.
    Citations: 38     Fields:    Translation:Humans
  102. Sax PE. Editorial commentary: can we break the habit of routine CD4 monitoring in HIV care? Clin Infect Dis. 2013 May; 56(9):1344-6. PMID: 23315314.
    Citations: 13     Fields:    Translation:HumansCells
  103. Schackman BR, Haas DW, Becker JE, Berkowitz BK, Sax PE, Daar ES, Ribaudo HJ, Freedberg KA. Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. Antivir Ther. 2013; 18(3):399-408. PMID: 23264445.
    Citations: 6     Fields:    Translation:Humans
  104. McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE, Gerschenson M. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. J Infect Dis. 2013 Feb 15; 207(4):604-11. PMID: 23204164.
    Citations: 9     Fields:    Translation:HumansCells
  105. Ribaudo HJ, Daar ES, Tierney C, Morse GD, Mollan K, Sax PE, Fischl MA, Collier AC, Haas DW. Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis. 2013 Feb 01; 207(3):420-5. PMID: 23148286.
    Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
  106. Mollan K, Daar ES, Sax PE, Balamane M, Collier AC, Fischl MA, Lalama CM, Bosch RJ, Tierney C, Katzenstein D. HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. J Infect Dis. 2012 Dec 15; 206(12):1920-30. PMID: 23148287.
    Citations: 11     Fields:    Translation:HumansCells
  107. Zolopa A, Gallant J, Cohen C, Sax P, Dejesus E, Mills A, Wohl D, Liu H, Rhee M, Szwarcberg J. Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-naïve HIV-1-infected patients. J Int AIDS Soc. 2012; 15(6):18219. PMID: 23234891.
    Citations:    
  108. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N, Sax PE. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS. 2012 Jul 17; 26(11):1371-85. PMID: 22546988.
    Citations: 41     Fields:    Translation:HumansCells
  109. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012 Jun 30; 379(9835):2439-2448. PMID: 22748591.
    Citations: 94     Fields:    Translation:HumansCellsCTClinical Trials
  110. Gandhi RT, Sax PE, Grinspoon SK. Metabolic and cardiovascular complications in HIV-infected patients: new challenges for a new age. J Infect Dis. 2012 Jun; 205 Suppl 3:S353-4. PMID: 22577207.
    Citations: 8     Fields:    Translation:Humans
  111. Szent-Gyorgyi LE, Desai S, Kim D, Sax PE, Greenberg JO. Removing legal barriers to high-quality care for HIV-infected patients. N Engl J Med. 2012 Apr 05; 366(14):1268-70. PMID: 22475590.
    Citations: 1     Fields:    Translation:Humans
  112. Aberg JA, Tebas P, Overton ET, Gupta SK, Sax PE, Landay A, Falcon R, Ryan R, De La Rosa G. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012 Oct; 28(10):1184-95. PMID: 22352336.
    Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
  113. Lockman S, Sax P. Treatment-for-prevention: clinical considerations. Curr Opin HIV AIDS. 2012 Mar; 7(2):131-9. PMID: 22227588.
    Citations: 8     Fields:    Translation:HumansCells
  114. Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One. 2012; 7(2):e31591. PMID: 22384040.
    Citations: 30     Fields:    Translation:Humans
  115. Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR. Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development. HIV Clin Trials. 2012 Jan-Feb; 13(1):1-10. PMID: 22306583.
    Citations: 4     Fields:    Translation:Humans
  116. Sax PE. New HCV treatments look promising for HIV/HCV-coinfected patients. J Watch AIDS Clin Care. 2012 Jan; 24(1):3-4. PMID: 26223039.
    Citations:    Fields:    
  117. Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011 Oct 15; 204(8):1191-201. PMID: 21917892.
    Citations: 53     Fields:    Translation:HumansCellsCTClinical Trials
  118. Sax PE. Antiretroviral therapy: now "it just works". Clin Infect Dis. 2011 Sep; 53(6):605-8. PMID: 21844007.
    Citations: